EFTRW eFFECTOR Therapeutics, Inc. - Warrant
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. This security was issued by eFFECTOR Therapeutics, Inc., whose common stock symbol is EFTR.
$0.15 0.00 (0.00%)
As of 03/23/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Warrants
Category3: Operating Companies
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation:
IPO date: 08/25/2021
Outstanding shares: 5,833,333
Average volume: 14,803
Market cap: $15,205,077
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: